FDA looking into death of 14-year-old trial participant
Updated: Tuesday, March 5 2013, 08:15 AM EST
(NEWSCHANNEL 3) - Federal health regulators say they've stopped Amgen's studies of its thyroid drug Sensipar, after the death of a 14-year-old patient in a company trial.
The FDA says that it's gathering information about the death, but has shut down all studies of the drug in children.
Sensipar is approved for adults to treat over-activitiy of the parathyroid gland.
Amgen had been studying the drug to see whether it works in children.